ECMO Machine Market Development | Industry Report 2021

According to the new market research report ECMO Machine Market is expected to reach USD 305.3 Million by 2021 from USD 247.2 Million in 2016, at a CAGR of 4.3%. A number of key players are competing against each other to expand their existing customer base. Getinge Group (Sweden), Medtronic plc (Ireland), and LivaNova PLC (U.K.) are the top three players of the extracorporeal membrane oxygenation (ECMO) machine market. These players jointly accounted for a share of 65% to 70% of the total ECMO machine market in 2015.

Download Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=255167654

The growth of the extracorporeal membrane oxygenation ECMO machine market is expected to be cantered in the Asia-Pacific region. Japan is a mature market for ECMO machines, whereas China and India are emerging markets. The reimbursement policies in Japan encourage the adoption of highly advanced techniques such as ECMO. As a result, the Japanese population receives access to healthcare facilities at affordable costs.

In the Asia-Pacific countries, various conferences are being organized to create awareness of advancements and the emerging usage of ECMO systems. Conferences establish a platform for the exchange of new advancements occurring in the field of ECMO systems. They also offer players the opportunity to showcase their products and communicate with stakeholders, while helping scientists and researchers to exchange experiences and build research relations.

Some of the recent events in the Asia-Pacific region includes Asia-Pacific ELSO Conference 2017 (Australia, October 2017), ECMO Current Challenges and Future Perspectives (India, 2016), Extracorporeal Life Support Organization (ELSO), and Asia Pacific ELSO (APELSO) 2013 Meeting (China, 2013).

Some of the recent events in the Asia-Pacific region includes Asia-Pacific ELSO Conference 2017 (Australia, October 2017), ECMO Current Challenges and Future Perspectives (India, 2016), Extracorporeal Life Support Organization (ELSO), and Asia Pacific ELSO (APELSO) 2013 Meeting (China, 2013).

Get report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=255167654

Most of the leading players in the market are pursuing the strategies of approvals, product launches, agreements & partnerships, expansions, and other strategies (rebranding, acquisition, website launch, product development, and market deployment).

Pacemakers Market Development | Industry Report 2023

A pacemaker is a medical device used when the heart is unable to produce electrical impulses naturally. When the heart’s natural pacemaker is defective or when the electrical pathways of the heart are blocked, it can cause irregular heartbeats, as known as arrhythmias. A pacemaker uses electrical pulses to prompt the heart to beat at a normal rate to treat arrhythmias.

The development of implantable micro pacemakers for fetal use is further expected to propel the pacemakers market growth for liquid milk replacers. MarketsandMarkets expects the global pacemakers market to grow from USD 4.4 billion in 2018 to USD 4.9 billion by 2023, at a CAGR of 2% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=243344814

The implanted pacemakers segment, by implantability, is projected to grow at the higher CAGR during the forecast period. These devices are often placed in the chest area, just under the collarbone, to send electrical signals to start or regulate the patient’s heartbeat. The increasing prevalence of CVDs and growing awareness on their long-term impacts, and introduction of MRI compatible & leadless, miniaturized implantable pacemakers are driving the preference for advanced treatment options such as MRI Compatible pacemakers.

The dual-chamber pacemakers segment, by technology, is projected to grow at the highest CAGR during the forecast period. A dual-chamber pacemaker has two leads and can be external or implantable. It connects to both chambers on the right side of the heart—the right atrium and the right ventricles—and can coordinate functions between the atria and ventricles. They are recommended for patients who have symptomatic bradycardia caused by sick sinus syndrome, atrioventricular block, or a combination of both. Due to the higher efficiency and cost-effectiveness of dual-chamber pacemakers in atrioventricular block or sick sinus syndrome over single-chamber which will impact their growth at a significant rate

The MRI compatible pacemakers segment, by type, is projected to grow at the highest CAGR during the forecast period. The development of MRI Compatible pacemakers is a major advancement in the pacemakers market. It is estimated that 75% of patients who currently have an implantable cardiac pacemaker will need MRI scans during their lifetimes. With a focus on catering to end-user demands, most prominent players in this pacemakers market have developed and launched technologically advanced MRI Compatible pacemakers in recent years. Factors such as growing number of patients with implanted pacemakers and the increasing need for MRI scans in the geriatric population, as patients in this age group are also more likely to have cardiac devices such as pacemakers.

The hospitals & cardiac centers segment, by end user, is projected to grow at the highest CAGR during the forecast period. Factors such as the large number of cardiovascular surgical procedures performed in hospitals, improving healthcare infrastructure, and favorable reimbursement scenario are driving the growth of the pacemakers market for hospitals & cardiac centers.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=243344814

In terms of geographical coverage, the pacemakers market has been segmented into 4 regions, namely, North America, Asia Pacific (APAC), Europe, RoW (Rest of the World). APAC is projected to record the highest growth rate during the forecast period. This can largely be attributed to the increasing prevalence of CVDs in these countries due to various factors such as increasing adoption of sedentary lifestyles, changing diets, increasing stress, and habitual smoking and drinking.

Sinus Dilation Devices Market Development | Industry Report 2023

According to research report the sinus dilation devices market is expected to reach USD 2.78 billion by 2023 from USD 1.80 billion in 2018, at a CAGR of 9.1%. The growth of the market can be attributed to the high prevalence of chronic sinusitis, growing preference for minimally invasive procedures, benefits of balloon sinuplasty/sinus dilation over conventional sinus surgeries, and favorable reimbursement scenario for sinus procedures in developed countries

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=64349810

Benefits of balloon sinuplasty / sinus dilation over conventional sinus surgeries to drive the growth of sinus dilation devices market

ENT Clinics/In Office
Increasing number of treatable patients in ENT clinics, faster recovery time, cost-effectiveness, and growing preference for minimally invasive techniques are some of the factors driving the growth of this segment. In 2016, out of the 188,000 patients suffering from chronic sinusitis, 160,000 (85%) patients performed the balloon sinus dilation procedure in ENT clinics/in office in the US (Source: Entellus Presentation 2017.

Ambulatory Surgical Centres (ASCs)
Ambulatory surgical centres (ASCs) provide healthcare services and primary care to patients in an outpatient capacity. The minimally invasive procedure such as balloon sinus dilation can be easily performed in ASCs. Factors such as better infrastructure in ASCs are driving the growth of this segment. The cost-effectiveness coupled with the better reimbursement scenario than hospitals is also driving the growth of this segment.

Hospitals
Hospitals is one of the patient care settings where sinus dilation devices are extensively used.
This segment holds the largest market share due to high number of outpatient sinus dilation procedures, the advantages of having integrated healthcare facilities, the availability of technologically advanced infrastructures, and the ability to perform complex sinus surgeries.

North America is expected to dominate the sinus dilation devices market in 2018
In 2018, North America is expected to dominate the market followed by Europe. The large share of this geographical segment is attributed to rapidly increasing geriatric population, rising prevalence of chronic sinusitis, higher adoption of new technologies among ENT surgeons and otolaryngologists, favorable reimbursement scenario, and the presence of major players in this region.

Get Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=64349810

Key players in the Sinus Dilation Devices Market include The major players in the market are Entellus Medical Inc. (a subsidiary of Stryker) (US), Acclarent Inc. (a subsidiary of Johnson & Johnson) (US), Medtronic plc (Ireland), Smith & Nephew plc (UK), Intersect ENT Inc. (US), and Olympus Corporation (Japan). Other players in the market include Meril Life Sciences Pvt. Ltd. (India), SinuSys Corporation (US), InAccel (India), Jilin Coronado Medical Ltd. (China) and dalENT Medical (US). These players are increasingly undertaking mergers and acquisitions, and product launches to develop and introduce new technologies and products in the sinus dilation devices market.

eHealth Market Development | Industry Report 2023

According to the new market research report eHealth Market is expected to reach USD 132.35 Billion by 2023 from USD 47.60 Billion in 2018, at a CAGR of 22.7%.
Factors such as the growing need to manage regulatory compliance through the use of eHealth solutions, the need to curtail escalating healthcare costs, increasing government initiatives supporting the use of eHealth solutions and services, the high prevalence of chronic diseases, shift towards patient-centric healthcare delivery, and rising usage of big data are majorly driving the growth of this market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=11513143

Based on product and service, the eHealth market is segmented into eHealth solutions and eHealth services. The eHealth services segment is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to factors such as the rising demand for availing medical consultation online, rapidly emerging new technologies in healthcare, the demand for home healthcare services, and the use of telecommunication and multimedia technologies combined within mobile and wireless healthcare delivery systems.

By type of eHealth solutions, the chronic care management apps are expected to register the highest CAGR during the forecast period. This can be attributed to the growing incidence of chronic diseases, high penetration of mobiles, and increasing adoption of mHealth solutions owing to various benefits such as ease of use and reduced costs offered by these solutions across the globe.

Based on type of eHealth services, the remote monitoring services segment is expected to register the highest CAGR during the forecast period. This can be attributed to the increasing incidence of chronic diseases across the globe and the widespread preference of patients for home healthcare and rehabilitation due to the convenience of these services.

Based on end user, the healthcare consumers segment is expected to register the highest CAGR during the forecast period. Factors such as the rising demand for personalized care, increased awareness for telehealth services, and high penetration of digital technologies among consumers are contributing to the high adoption of eHealth solutions among healthcare consumers.

The Asia Pacific region is expected to register the highest growth rate in the global eHealth market during the forecast period. Growing medical tourism, growing consumerism in the healthcare industry, accelerated economic growth of countries in the region, the implementation of new ICT guidelines, and the implementation of eHealth programs are the factors propelling the growth of the market in this region.

Get Sample Pages: https://www.marketsandmarkets.com/requestsample.asp?id=11513143

Emerging markets such as China, India, and Australia have a high potential for growth in the eHealth market mainly due to the rising government investments and reforms to modernize healthcare infrastructure, growing purchasing power of consumers, increasing government initiatives for infrastructural development, and the rising need to control the soaring healthcare costs. In addition, as the patient population in China and India is large and diverse, population health management through the use of effective eHealth solutions and services plays a central role in providing cost-effective and quality clinical care to patients, thereby further generating a significant growth opportunity for the players competing in the global eHealth during the forecast period.

Clinical Microbiology Market Development | Industry Report 2023

According to research report the clinical microbiology market is expected to reach USD 4.95 billion by 2023 from USD 3.63 billion in 2018 growing at a CAGR of 6.4% during forecast period.
Growth in clinical microbiology market can be attributed to factors such as rising incidence of infectious diseases and growing outbreak of epidemics and increased funding and public-private investments.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=219135367

Market Size Estimation
A detailed market estimation approach was followed to estimate and validate the size of the clinical microbiology market and other dependent submarkets, as mentioned above. The key players in the clinical microbiology market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. Research methodology includes the study of the annual and quarterly financial reports of the top market players as well as interviews with industry experts for key insights (both quantitative and qualitative trends) on the clinical microbiology market. All percentage shares, splits, and breakdowns were determined by using secondary sources and verified through primary sources.

The global clinical microbiology market is segmented by product, disease area, end user, and region. On the basis of products, the clinical microbiology market is segmented into instruments, and reagents.

estimate the market size includes the following:
• The key players in the industry and markets have been identified through extensive secondary research.
• The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
• All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Get Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=219135367

Geographically, Asia Pacific market is expected to grow at the highest CAGR from 2018 to 2023. Key factors driving the growth of the market in APAC are the growing number of hospitals and clinical diagnostic laboratories in developing APAC countries; expanding research capabilities for the development of innovative and affordable clinical microbiology testing procedures across India, China, and Japan; and the rising incidence of infectious diseases in the region.

Biopsy Devices Market Top Players and Growth Strategies | Industry Report 2022

According to research report the biopsy devices market is expected to reach USD 2.42 billion by 2022 from USD 1.74 billion in 2017, at a CAGR of 6.8% from 2017 to 2022.

The report analyzes the global biopsy devices market by product, guidance technique, application, end user, and region. Based on product, the global market is segmented into needle-based biopsy instruments, procedure trays, localization wires, and other products (forceps, markers, probes, punches, curettes, and sutures). In 2016, the needle-based biopsy instruments segment accounted for the largest share of global market mainly due to the increasing preference for minimally invasive surgeries and higher preference for needle-based biopsies over open surgical biopsies.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=132886515

Based on application, the global market is segmented into breast biopsy, lung biopsy, colorectal biopsy, prostate biopsy, and others. The breast biopsy segment accounted for the largest share of the global market in 2016. The rising prevalence of breast cancer and growing awareness about the disease are driving market growth in this segment.

Based on guidance technique, the biopsy devices market is segmented into ultrasound-guided biopsy, stereotactic-guided biopsy, magnetic resonance imaging (MRI)-guided biopsy, and other guidance techniques (positron emission tomography, fluoroscopy, and thermography). In 2016, the ultrasound biopsy segment dominated the market.

Based on end user, the market is segmented into hospitals, diagnostic & imaging centers, and academic & research institutes. In 2016, hospitals formed the largest end-user segment of the market. This can be attributed to the growth in the healthcare sector in emerging economies along with the increase in the out-of-pocket healthcare expenditure and increase in the number of hospitals.

Players in the global biopsy devices market, such as Becton, Dickinson and Company (U.S.), Devicor Medical Products, Inc. (U.S.), Argon Medical Devices, Inc. (U.S.), Cardinal Health, Inc. (U.S.), and Boston Scientific Corporation (U.S.) are focusing on increasing their presence in the high-growth markets through agreements, expansions, and acquisitions. Olympus Corporation (Japan), Cook Group Incorporated (U.S.), and Boston Scientific Corporation (U.S.) are some of the players focusing on organic growth strategy of new product launches to enhance their market presence.

C. R. Bard dominated the market due to its broad biopsy devices product portfolio. It operates in around 100 countries outside the U.S. The company manufactures medical devices in the field of vascular therapy, urology, oncology, and surgical specialties. C. R. Bard has a wide product portfolio for biopsy, including vacuum-assisted devices, core needle biopsy products, localization wires, breast tissue markers, and probes.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=132886515

Becton, Dickinson and Company is another prominent player in the market. The company is engaged in the development, manufacturing, and marketing of medical devices, instrument systems, and reagents. BD operates through two business segments—BD Medical and BD Life Sciences. The company offers biopsy products through its medication and procedural solutions segment, which operates under its Medical division.

Interventional Cardiology Devices Market Development | Industry Report 2022

According to research report the interventional cardiology devices market is expected to reach USD 20.85 billion by 2022 from USD 14.52 billion in 2017, at a CAGR of 7.5%.

Interventional cardiology devices are devices that are used to unclog blood vessels and restore normal blood flow. The market for these devices is expected to reach USD 20.85 billion by 2022 from USD 14.52 billion in 2017, at a CAGR of 7.5% during the forecast period. Growth in this market is mainly driven by factors such as the rapidly increasing geriatric population and technological advancements in interventional cardiology devices.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=548

Other factors supporting market growth include the increasing incidence of cardiovascular diseases, rising healthcare expenditure in emerging, improving healthcare infrastructure across the globe.
On the basis of type, the interventional cardiology devices market is categorized into angioplasty balloons, angioplasty stents, catheters, plaque modification devices, hemodynamic flow alteration devices, and other interventional cardiology devices. The plaque modification devices segment is expected to register the highest growth during the forecast period. Growth in this market is mainly due to the increasing adoption of these devices for plaque removal in arteries due to their effectiveness.

The angioplasty stents market is further segmented into bare-metal stents, drug-eluting stents, and bioresorbable stents. The bioresorbable stents segment is estimated to register the highest growth during the forecast period. Growth in this segment can be attributed to the benefits associated with the use of these stents, such as the dissolvability feature which minimizes the risk of restenosis after the interventional procedure.

The other interventional cardiology devices market is further classified into guidewires, vascular closure devices, introducer sheaths, and balloon inflation devices. The vascular closure devices segment is estimated to grow at the highest rate during the forecast period. The increasing demand for vascular closure in minimally invasive interventional cardiology procedures and technological advancements in these devices are driving the demand for vascular closure devices in the other interventional cardiology devices segment.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=548

The interventional cardiology devices market is geographically segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). Asia Pacific is expected to register the highest growth due to the improving healthcare infrastructure, the heavy burden of cardiovascular diseases, rising healthcare expenditure, and growth in the demand for interventional cardiology devices.
Given the immense opportunities in the major applications of interventional cardiology devices, market leaders and emerging players are increasingly focusing on the market in the segments mentioned above to increase their revenues and are also looking to expand their reach to emerging economies

Surgical Microscopes Market Healthy Growth Rate in the Coming Years | Industry Report 2021

According to research report the global surgical microscopes market is projected to reach USD 915.6 million by 2021 from USD 508.1 million in 2016, growing at a CAGR of 12.5% during the forecast period. The global surgical microscopes market is segmented based on application, end user, and region.

The surgical microscopes market is highly competitive in nature. Some of the major players in this market include Novartis AG (Switzerland), Danaher Corporation (U.S.), Topcon Corporation (Japan), and Carl Zeiss AG (Germany). The strong position of these companies in the market can primarily be attributed to their global presence and broad product portfolio. Other major players in the market include KARL KAPS GMBH & Co. KG (Germany), Alltion (Wuzhou) Co. Ltd. (China), and ARRI Medical (ARRI Group) (Germany).

Please share your specific interest to serve you better
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=179225920

Geographical overview -
The Asia-Pacific region (comprising China, India, and RoAPAC) is expected to grow at the highest CAGR during the forecast period. The high growth in this regional segment can primarily be attributed to the presence of high-growth markets such as Japan, China, India, South Korea, Taiwan, Australia, and Singapore. In recent years, the Asia-Pacific market for surgical/operating microscopes has witnessed significant growth due to improving R&D infrastructure, rising focus of market players, and increasing government initiatives.

The global surgical microscopes market is segmented based on application, end user, and region. Based on application, the market is segmented into neuro and spine surgery, plastic and reconstructive surgery, ophthalmology, gynaecology and urology, oncology, dentistry, ENT surgery, and documentation.

Market growth factors –
• The increasing use of fluorescence image-guided surgery (FIGS),
• Increase in the number of surgeries and growing demand for MIS,
• Advancements in healthcare facilities,
• Technological advancements, and customized microscopy solutions


Market Segmentation:

• Based on application, the market is broadly segmented into neuro and spine surgery, plastic and reconstructive surgery, ophthalmology, gynaecology and urology, oncology, dentistry, ENT surgery, and documentation. In 2016, the neuro and spine surgery segment is expected to account for the largest share of the market due to the increasing demand for surgical/operating microscopes in neurosurgery.
o However, the oncology segment is expected to grow at the highest CAGR during the forecast period. This can be attributed to the increasing prevalence of cancer around the world.

• On the basis of end user, the surgical microscopes market is segmented into hospitals and outpatient facilities. In 2016, hospitals are estimated to account for the largest share of the global surgical microscopes market. The growing usage of surgical/operating microscopes in complex neurology, ENT, and dental procedures, and implementation of less-invasive surgical instruments during MIS procedures in hospitals are key market drivers in this end-user segment. In 2016, North America is expected to account for the largest share of the global surgical microscopes market.
o Factors such as the growing demand for minimally invasive surgical procedures, infrastructural advancements in healthcare facilities, and increase in the number of surgeries are driving the growth of the North American surgical microscopes market.

Get Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=179225920

Prosthetic Heart Valves Market Top Players | Industry Report 2022

According to research report the global prosthetic heart valves market is projected to reach USD 8.86 Billion by 2022 from USD 4.84 Billion in 2017, at a CAGR of 12.9%. The report covers the artificial heart valves which are implanted in the hearts of patients suffering from heart valve disease (HVD). Factors such as rising geriatric population and the subsequent growth in the prevalence of heart valve disease (HVD), regulatory approvals for new and advanced prosthetic heart valves, increasing government funding for heart valve research, rising awareness about HVD, and favorable reimbursement scenario for prosthetic heart valves are driving the growth of the prosthetic heart valves market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=245407958

A number of key players in this market are competing against each other in order to expand their existing customer base. The prosthetic heart valves market, by type, is categorized as transcatheter heart valves, tissue heart valves, and mechanical heart valves. In 2016, Edwards Lifesciences Corporation (U.S.) and Medtronic plc (Ireland) dominated both, the transcatheter heart valves and the tissue heart valves market segments; the mechanical heart valves market was dominated by St. Jude Medical, Inc. (an Abbott Laboratories Company) (U.S.) and LivaNova PLC (U.K.). The prosthetic heart valves market is dominated by Edwards Lifesciences Corporation (U.S.), Medtronic plc (Ireland), St. Jude Medical, Inc. (an Abbott Laboratories Company) (U.S.), Boston Scientific Corporation (U.S.), LivaNova PLC (U.K.), Symetis SA (Switzerland), JenaValve Technology, Inc. (Germany), CryoLife, Inc. (U.S.), TTK Healthcare Limited (India), Colibri Heart Valve, LLC (U.S.), Lepu Medical Technology Co., Ltd. (China), and Braile Biomédica (Brazil).

Edwards Lifesciences Corporation (U.S.) dominated the global transcatheter heart valves market with a share of 58% in 2016. The company also dominated the tissue heart valves market with a share of 45% in 2016. The company is a pioneer in the development of heart valve products and is one of the leading manufacturers of heart valves and repair products for the replacement or repair of defective heart valves. Edwards Lifesciences primarily focuses on growth strategies such as approvals and product launches, followed by marketing and promotion. For instance, in August 2016, it received the U.S. FDA approval for its INTUITY Elite Valve System designed to facilitate minimally invasive surgeries and streamline complex aortic valve replacements. The company also focuses on acquiring companies to gain their valuable insights in the field of heart valve systems. For instance, in January 2017, the company acquired Valtech Cardio Ltd. (Israel), a developer of Cardioband System for transcatheter repair of the mitral and tricuspid valves.

Edwards Lifesciences also organizes educational symposia and customer training sessions to create awareness on its products and technologies. The company’s sales growth was led by the transcatheter heart valves therapy segment, which benefited from the launch of the SAPIEN 3 transcatheter heart valve in the U.S. (July 2015), Europe (January 2014), and Japan (March 2016). Edwards Lifesciences has succeeded in creating a strong foothold in the heart valves market owing to its diversified product portfolio, wide geographic reach, focus on innovation and research, and growing number of product launches.

Medtronic plc (Ireland) accounted for a share of 30% of the global transcatheter heart valves market and 26% of the global tissue heart valves market in 2016. The company develops, manufactures, and markets a broad range of medical devices, therapies, and services for various chronic diseases. The research and development unit of the company focuses on developing new products, improving existing products and therapies, and expanding the indication and application of its products. For instance, in March 2017, the company launched a transcatheter heart valve—CoreValve Evolut PRO. The company commands a major share of the prosthetic heart valves market on account of its diversified product portfolio of heart valves systems, widespread geographical presence, focus on organic and inorganic growth strategies, strong focus on R&D, and aggressive marketing and sales strategies.

St. Jude Medical, Inc. (U.S.) accounted for a share of 52% of the global mechanical heart valves market in 2016. The company offers a number of products in the prosthetic heart valves market through the Structural Heart Products segment; this segment offers heart valve replacement and repair products and structural heart defect treatment devices such as tissue valves and mechanical valves (SJM Regent Heart Valves). The net sales of its mechanical heart valves segment declined from 2014 to 2015 owing to the market preference for tissue valves. The company focuses on R&D to support its long-term growth opportunities.

Get Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=245407958

In May 2015, St Jude launched the Trifecta valve with glide technology in the U.S. Trifecta is the company’s most advanced tissue valve for the treatment of patients diagnosed with unhealthy, damaged, or malfunctioning aortic heart valves. St Jude has a market presence in the U.S., Europe, Japan, and Asia-Pacific, and has more than 20 principal operations and manufacturing facilities worldwide. It has gained a major share of the mechanical heart valves market on account of its comprehensive solutions, wide geographical presence, aggressive marketing and sales strategies, and focus on research and development for product innovation.

Restorative Dentistry Market Recent Development | Industry Report 2022

According to the new market research report Restorative Dentistry Market is expected to reach USD 21.27 Billion by 2022 from an estimated USD 15.60 Billion in 2017, at a CAGR of 6.4% during the forecast period.

Factors such as rapid growth in the geriatric population and the associated increase in the prevalence of edentulism, growing dental tourism in emerging markets, rising incidence of dental caries and other periodontal diseases, increasing outsourcing of customization and fabrication of restorative and prosthetic products to restorative dentistry, and increasing demand for restorative dentistry are driving the growth of the global restorative dentistry market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=210042423

In this report, the market is segmented based on product, end user, and region. Based on product, the restorative dentistry market is segmented into restorative materials, implants, prosthetics, and restorative equipment. In 2016, the restorative materials segment accounted for the largest share of the global restorative dentistry market and is expected to register the highest CAGR during the forecast period. The large share and high growth of this segment can primarily be attributed to the growing number of tooth repair procedures, high cost of restorative materials, increasing adoption of customized prosthetics, and increasing demand for cosmetic dentistry.

Based on equipment, the restorative dentistry market is segmented into CAD/CAM systems, handpieces, rotary instruments, light curing equipment, casting devices, mixing devices, furnaces, and articulating equipment. In 2016, the CAD/CAM systems segment accounted for the major share of the global restorative dentistry market. This is primarily due to the increasing use of digital manufacturing processes in dentistry and growing demand for fabricating or customizing restoration models.

Based on end user, the restorative dentistry market is segmented into hospitals & clinics, dental schools & research institutes, and dental laboratories. The hospitals & clinics segment accounted for the major share of the global restorative dentistry market and is expected to register the highest CAGR during the forecast period. The large share of this end-user segment is attributed to the increasing number of dental clinics and hospitals especially in emerging markets, rapid adoption of advanced technologies in these settings, and growth in the target patient population.

The Asia Pacific region is expected to register the highest growth rate in the restorative dentistry market during the forecast period. The rising geriatric population, growing dental tourism, increasing focus of prominent players on emerging Asian countries, increasing healthcare expenditure (coupled with the rising disposable income), rising awareness on oral healthcare, and increasing willingness of people to spend more on dental care to maintain dental aesthetics in this region.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=210042423

Prominent players in this market include DENTSPLY SIRONA Inc. (US), Danaher Corporation (US), 3M Company (US), Zimmer Biomet Holdings, Inc. (US), Ultradent Products, Inc. (US), GC Corporation (Japan), Institut Straumann (Switzerland), Mitsui Chemicals, Inc. (Japan), Septodont Holding (France), Ivoclar Vivadent AG (Liechtenstein), and VOCO GmbH (Germany). These companies are also focusing on developing new innovative technologies and products to their portfolio, which in turn helps them to strengthen their presence in the market.

Neuroscience Antibodies Market Top Players and Growth Strategies

According to research report the Neuroscience Antibodies Market is expected to reach USD 4.18 Billion by 2023 from USD 2.57 Billion in 2018, at a CAGR of 10.2%. Growth in this market is driven by the rising incidence of neurological diseases, increasing investments in neuroscience research, and growth in the pharmaceutical and biotechnology industries. On the other hand, quality and cost concerns over the production of antibodies are the major factor restraining the growth of this market.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=129888612

The Neuroscience Antibodies Market are segmented based on product, technology, application, end user, and region. Based on product, the Neuroscience Antibodies Market are segmented into consumables and instruments. The consumables segment is expected to account for the largest market share in 2018 and is expected to register the highest CAGR during the forecast period. The consistent usage of consumables and their frequent purchases, and rising government initiatives in the genomics and proteomics research sector is the major factor supporting the growth of the consumables segment during the forecast period. Based on type, the consumables market is segmented into reagents, antibodies, and assays kits. The reagents segment is expected to account for the largest share in 2018. The large share of this segment is attributed to the high consumption of reagents in various routine assays and techniques.

Based on technology, the Neuroscience Antibodies Market are segmented into immunoassays/immunochemistry, molecular diagnostics, clinical chemistry, and other technologies. The immunoassays/immunochemistry technology segment is expected to register the highest CAGR during the forecast period. The high growth of this segment is attributed to the development of novel antibodies and assays for immunoassay techniques, technological developments in immunoassays, and rising government initiatives in the genomics and proteomics research sector.

Based on end user, the Neuroscience Antibodies Market are segmented into pharmaceutical and biotechnology companies, academic and research institutes, and hospitals and diagnostic centres. The pharmaceutical and biotechnology companies segment accounted for the largest market share in 2018. The high uptake of neuroscience antibodies in the drug discovery and development process and the presence of many pharmaceutical players in this market are driving the Neuroscience Antibodies Market for this end-user segment.

Get Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=129888612

Among the four regional segments, Asia is expected to grow at the highest CAGR during the forecast period. The high growth in the Asian market is attributed to factors such as favourable regulatory guidelines, rising incidence of neurological diseases, growing presence of market players in emerging economies, and favourable government investments in the life sciences sector.

Competent Cells Market Leading Players and Growth Strategies

According to research report the global competent cells market is projected to reach USD 2.22 billion by 2022 from USD 1.37 billion in 2017, at a CAGR of 10.2%.

• By type, the chemically competent cells segment is expected to dominate the market in 2017
• By application, the cloning segment is expected to dominate the market in 2017
• By end user, the academic research institutes segment is expected to dominate the market in 2017
• North America to dominate the competent cells market in 2017

Download PDF Brochure: https://www.marketsandmarkets.com/requestsampleNew.asp?id=265815900

Competent cells are E.coli cells that possess altered cell walls which enable the assimilation of foreign DNA. These cells are widely used in cloning and protein expressions applications. Advancements in molecular cloning research due to the emergence of new technologies and increasing commercial demand for molecular cloned products and recombinant proteins are the major factors driving the growth of the competent cells market.

Product launches, acquisitions, and partnerships were some of the major strategies followed by key players in the competent cells market. These strategies were adopted by—Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), New England Biolabs (U.S.), GenScript Biotech Corporation (China), and Agilent Technologies, Inc. (U.S.).

Target Audience for this Report:
• Competent cell manufacturers
• Research instrument manufacturers
• Competent cell distributors
• Various research and consulting companies
• Research laboratories and research institutes
• Universities and CROs

Get Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=265815900

Thermo Fisher Scientific, Inc. is one of the key players in the competent cells market. The company focuses on product launches, acquisitions, and agreements to enhance its presence in the market. In January 2016, Thermo Fisher acquired Affymetrix (U.S.), to strengthen its leadership in biosciences and to create new market opportunities in genetic analysis. Similarly, in February 2014, the company acquired Life Technologies Inc. (U.S.). After this acquisition, Thermo Fisher created a new business segment—Life Sciences Solutions— which includes a broad range of protein expression systems and their related products.

Medical Device Contract Manufacturing Market Growth Prospects & Forecast 2024

According to research report the Medical Device Contract Manufacturing Market is expected to reach USD 91.3 billion by 2024 from an estimated USD 55.0 billion in 2019, at a CAGR of 10.6%. The key factors driving the growth of the Medical Device Outsourcing Market include the overall growth of the medical devices market as a whole (mainly due to rising disease prevalence, life expectancy, and the geriatric population), increasing technological adoption in the medical devices industry leading to electronically integrated devices, and low returns on investment due to the rising cost of in-house manufacturing.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=170622851

The medical device contract manufacturing market is highly fragmented with the top 15 companies accounting for approximately 25% of the total market. As of 2018, Flex, Ltd. (Singapore) and Jabil, Inc. (US) together accounted for approximately 10% of the global medical device contract manufacturing market.

Jabil Inc. (US) was the leader in the medical device contract manufacturing market in 2018. The company offers a focused range of products such as diagnostic devices, diabetes care devices, ophthalmology devices, pharmaceutical drug delivery devices, and consumables for medical devices and services such as additive manufacturing, contract manufacturing, quality management services, and final goods assembly services. It also offers advanced manufacturing technologies such as electronic manufacturing services and automation in several manufacturing facilities worldwide such as Singapore, Mexico, China, and the US, among others.

Some of the other leading players competing in this market are Sanmina Corporation (US), Integer Holdings Corporation (US), Celestica Inc. (Canada), Plexus Corporation (US), Benchmark Electronics, Inc. (US), Gerresheimer AG (Germany), West Pharmaceutical Services, Inc. (US), Nortech Systems, Inc. (US), TE Connectivity, LTD. (Switzerland), Consort Medical PLC (UK), Nipro Corporation (Japan), Kimball Electronics Inc. (US), and Teleflex Incorporated (US).

Recent Developments
• In April 2019, West Pharmaceutical Services, Inc. (US) expanded its presence in the Asia Pacific region with a new sales office in Korea—West Pharmaceutical Services Korea Ltd.
• In March 2019, Nemera Development SA (France) partnered with Novo Nordisk (Denmark) to build a new manufacturing site in France to manufacture injectable devices.
• In October 2018, Phillips-Medisize Corporation (US) signed an agreement with InterSystem Corporation (US) to develop a third generation connected health platform.
• In July 2018, Jabil Inc. (US) acquired True-Tech Corporation (US), a manufacturer specializing in aerospace, semiconductor, and machined medical components for USD 95.9 million.

Get Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=170622851

Geographically, the Asia Pacific is expected to witness the highest CAGR during the forecast period, owing to factors such as the increasing demand for medical devices in this region due to the improving healthcare infrastructure, adoption of technologically advanced products, low cost of manufacturing, and the less stringent regulatory scenario for manufacturing of medical devices which promotes higher usage of medical devices as compared to most developed countries.

Contrast Media Market – Recent Developments | Industry Report 2027

According to research report the global contrast media market is expected to reach USD 8.68 billion by 2027 from USD 4.56 billion in 2018, at a CAGR of 3.9%. The major factors driving the growth of the contrast media/contrast agents market include increasing number of research and funding activities for research of contrast agents and their applications.

Please share your specific interest to serve you better:
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=911

North America to dominate the market in 2017
North America, Europe, Asia-Pacific, and Rest of the World (RoW) are the regions considered for a geographic analysis of the global contrast media/contrast agents market. North American contrast media/contrast agents market is expected to account for the largest share of the global contrast media/contrast agents market. However, the Asia Pacific contrast media/contrast agents market is expected to grow at the highest CAGR in the forecast period. This growth can be attributed to the increasing R&D investments and favorable demographic scenario in China, rising aging population and cancer incidence in Japan, growing investments in the Indian radiology market, and growing focus of market players & increasing government support in other APAC countries.

The prominent players in the global contrast media/contrast agents market include GE Healthcare (US), Bracco Imaging S.p.A. (Bracco) (Italy), Bayer HealthCare (Bayer) (Germany), and Guerbet Group (Guerbet) (France).

By modality, the X-ray/CT segment is expected to account for the largest share of the market in 2017
On the basis of modality, the market is segmented into X-ray/CT, MRI, and ultrasound procedures. In 2017, X-ray/CT procedures are expected to command the largest share of the global contrast media market. However, the ultrasound segment is expected to grow at the highest CAGR from 2017 to 2022. Growth in the ultrasound segment can largely be attributed to several advantages offered by ultrasound contrast agents over other contrast agents and the rising number of approvals for ultrasound contrast agents in the US, Europe, and Japan.

Get Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=911

By type, the iodinated contrast media segment is expected to account for the largest share of the market in 2017
On the basis of type, the contrast media/contrast agents market is segmented into iodinated contrast media, gadolinium-based contrast media, barium-based contrast media, and microbubble contrast media. In 2017, the iodinated contrast media segment is estimated to account for the largest share of the contrast media/contrast agents market, by type. However, the microbubble contrast media segment is expected to grow at the highest CAGR during the forecast period. The high growth of the microbubble segment can be attributed to the large number of on-going academic researches that are exploring various attributes of microbubbles in off-label indications for diagnosis as well as drug delivery.

Liquid Biopsy Market Size, Share, Trends | Industry Report 2022

The key factors driving the growth of this market include increasing prevalence of cancer, increasing preference for non-invasive procedures, initiatives undertaken by government and global health organizations, technological advancement to augment market revenues, rising emphasis on personalized medicine, and availability of funding for liquid biopsy R&D.

According to the new market research Liquid Biopsy Market is expected to reach USD 2,047.9 Million by 2022 from an estimated USD 715.7 Million in 2017, at a CAGR of 23.4%.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350

• By circulating biomarkers, circulating tumour cells is expected to account for the largest market share in 2017
• By clinical application, the therapy selection segment is expected to account for the largest market share in 2017
• By application, the cancer segment is expected to account for the largest market share in 2017
• By end user, the reference laboratories segment is expected to account for the largest market share in 2017

By product, the assay kits segment is expected to account for the largest share of the market in 2017
On the basis of product, the liquid biopsy market is broadly segmented into assays kits, instruments, and services. In 2017, the assay kits segment is expected to account for the largest share of this market. The increase in basic research and commercial applications of liquid biopsy, increase in demand for liquid biopsy tests, and the need for reliable and specific assays are expected to drive the market growth.

The key players in the global liquid biopsy market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), and MDx Health SA (US).

Get Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=13966350

North America is expected to dominate the market in 2017
North America is expected to account for the largest share of the liquid biopsy market in 2017, followed by Europe. A number of factors such as the easy accessibility and high adoption of advanced diagnostic technologies (such as PCR and NGS) among healthcare professionals, rising prevalence of cancer in the US and Canada, technological advancements in liquid biopsy products, and growing public and private funding to support research activities in the field of liquid biopsy are aiding market growth in the region.

Wearable Medical Devices Market Growth Factors and Industry Report 2022

Factors such as technological advances in medical devices, increasing penetration of smartphones and growing number of smartphone-based healthcare apps compatible with wearable devices, growing preference for wireless connectivity among healthcare providers, and increasing awareness about physical fitness are driving the growth of this market.

According to research report the wearable medical devices market is expected to reach USD 14.41 billion by 2022 from USD 6.22 billion in 2017, at a CAGR of 18.3%.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=81753973

Based on application, the wearable medical devices market is segmented into remote patient monitoring, home healthcare, and sports & fitness. The sports and fitness segment is expected to register the highest CAGR during the forecast period. The significant growth of segment is owing to factors such as the increasing focus on physical fitness among people to improve the quality of life and growing trend of tracking health progress.

Based on type, the wearable medical devices market is segmented into activity monitors, smartwatches, smart clothing, and patches. The activity monitors segment is expected register the highest CAGR during the forecast period. The high growth of this segment can be attributed to factors such as the rising adoption of sedentary and unhealthy lifestyles, rising prevalence of lifestyle diseases, and growing awareness of health and fitness.

Based on distribution channel, the wearable medical devices market is segmented into pharmacies, online channel, and hypermarkets. The pharmacies segment is expected to dominate the market during the forecast period. The growth of this segment is mainly attributed to factors such as increasing trend towards self-monitoring and non-invasive monitoring and diagnosis and substantial increase in the supply of wearable devices in pharmacies.

Among the four regional segments covered in the wearable medical devices market—north America, Europe, Asia Pacific, and the Rest of the World (RoW). Geographically, the wearable medical devices market in the Asia Pacific region is expected to register the highest CAGR during the forecast period. Growth in this regional segment is largely driven by the increased spending on healthcare, faster economic growth, presence of a huge population base, and increasing prevalence of diseases in the region. Furthermore, changes in lifestyle and increasing awareness on wellness and fitness are also expected to boost market growth in the region.

Spirometer Market – Business Growth Opportunities | Global Forecast 2023

The report studies the market on the basis of product type, mechanism, application, end user, and region. Market growth is largely driven by the rising global incidence of respiratory diseases, global population, and technological advancements in spirometer devices.

According to research report the global Spirometer Market is expected to reach USD 1,047 million by 2023 from USD 655 million in 2018, at a CAGR of 9.8%.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=18015659

The spirometry equipment market is geographically segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). Asia is expected to register the highest CAGR in the market during the forecast period. The high growth in this region can primarily be attributed to the rising geriatric population, high burden of respiratory diseases such as COPD and asthma, growing per capita income, increasing investments in the healthcare industry by key market players, rising demand for cutting-edge technologies, expansion of private-sector hospitals to rural areas in various APAC countries, and the presence of high-growth markets such as Japan, China, India, South Korea, Taiwan, Australia, and Singapore.

By product type, the spirometry equipment market is segmented into consumables & accessories, devices, and software. The consumables & accessories segment accounted for the largest share in 2018. The rising incidence of respiratory diseases and the growing geriatric population are the key factors driving the growth of this product segment.

By end user, the spirometry equipment market is segmented into hospitals, clinical laboratories, home care settings, and industrial settings. Hospitals accounted for the largest share of the spirometry equipment market in 2018 while the home care settings segment is expected to register the highest growth during the forecast period. The growing requirement for personalized lung monitoring is a key factor driving the growth of the spirometry equipment market for home care settings.

Based on application, the spirometry equipment market is segmented into COPD, asthma, and other applications. Among these, the COPD segment accounted for the largest share of the spirometry equipment market in 2018. The large share of this segment is mainly due to the high and growing prevalence of COPD globally and the easy diagnosis of COPD offered by spirometry.

Get Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=18015659

Key players in this market can explore the possibilities of expanding to the emerging economies of India and Brazil. These countries are going through a phase of rapid industrialization, leading to increasing pollution levels. This has created a need for monitoring lung conditions regularly, which increases the demand for spirometers.

Minimally Invasive Surgical Instruments Market Size, Share, Trends | Global Forecast 2021

With rising geriatric population, presence of a large patient pool undergoing surgical treatments, growing awareness about modern surgical instruments and techniques, and implementation of various initiatives to reduce the rising healthcare expenditure in Asia-Pacific, the demand for minimally invasive surgical instruments in this region is expected to grow, which in turn will compel the key players to expand their geographical presence in this region.

The market is segmented on the basis of product, application, and end user. By product, the market includes handheld instruments, electrosurgical instruments, inflation systems, guiding devices, auxiliary instruments, and cutter instruments.

Download Free Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=682

According to the new market research report Minimally Invasive Surgical Instruments Market is projected to reach USD 21.47 Billion by 2021 from USD 13.89 Billion in 2016, at a CAGR of 9.1%. Asia-Pacific is expected to grow at the highest rate.

• By product, the market includes handheld instruments, electrosurgical instruments, inflation systems, guiding devices, auxiliary instruments, and cutter instruments. The handheld instruments segment accounted for the largest share of the minimally invasive surgical instruments market.
• The applications included in this report are cardiothoracic surgery, cosmetic surgery/bariatric surgery, gastrointestinal surgery, orthopedic surgery, gynaecological surgery, vascular surgery, urological surgery, and others. The others segment includes ENT/respiratory surgery, neurological surgery, dental surgery, and pediatric surgery.
• End users included in this report are government hospitals, private hospitals and surgical clinics, and medical colleges. In 2015, the private hospitals and surgical clinics segment accounted for the largest share of the global minimally invasive surgical instruments market.

Geographical Overview -
The geographic segments included in this report are North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America is further segmented into the U.S. and Canada. In 2015, North America accounted for the largest share of the global minimally invasive surgical instruments market primarily due to the rising number of surgical procedures, growing government investments, growing geriatric population, and rising prevalence of lifestyle diseases in this region. With the rising geriatric population, presence of a large patient pool undergoing surgical treatments, growing awareness about modern surgical instruments and techniques, and implementation of various initiatives to reduce the rising healthcare expenditure in Asia-Pacific, the demand for minimally invasive surgical instruments in this region is expected to grow, which in turn will compel the key players to expand their geographical presence in this region.

Get Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=682

Leading Market Players -
Major players in the global minimally invasive surgical instruments market are Medtronic plc (Ireland), Ethicon, Inc. (U.S.), Aesculap, Inc. (Germany), Stryker Corporation (U.S.), and Smith & Nephew (U.K.). These players have a strong presence in major as well as emerging markets. Other players in this market are ConMed Corporation (U.S.), Abbott Laboratories (U.S.), Applied Biomedical Resources Corporation (U.S.), Microline Surgical (Japan), and Zimmer Biomet (U.S.).

Structural Heart Devices Market Leading Players and Business Strategies

According to research report the global structural heart devices market is projected to reach USD 15.08 billion by 2023 from USD 9.28 billion in 2018, at a CAGR of 10.2%. Growth in the structural heart devices market is mainly driven by factors such as the rising prevalence of structural heart diseases, regulatory approvals for new and advanced structural heart devices, favourable reimbursement scenario for structural heart procedures & devices, and increasing awareness about structural heart diseases.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=161123753

Players in this market compete to deliver superior and advanced technologies for heart valve repair and replacement. In 2017, the structural heart devices market was dominated by a few large players, namely, Edwards Lifesciences Corporation (US), Medtronic plc (Ireland), Abbott (US), Boston Scientific Corporation (US), and LivaNova plc (UK).

Edwards Lifesciences held the leading position in the global structural heart devices market in 2017 on account of its diverse portfolio of transcatheter and surgical heart valves. The company pursues organic as well as inorganic growth strategies, such as product launches & approvals and acquisitions to further increase its market share and strengthen its foothold in the surgical heart devices market. For instance, in December 2017, the company acquired Harpoon Medical Inc. (US). The unique beating-heart repair procedure for mitral valve patients of Harpoon Medical complements Edwards’ comprehensive portfolio of treatments for structural heart disease and reinforce its commitment to innovation in cardiac surgery. This acquisition was valued at USD 100 million.

Medtronic held the second position in the structural heart devices market in 2017. The company offers a comprehensive range of transcatheter and surgical heart valve products through its Coronary & Structural Heart division. The key percutaneous surgical products offered by the company include the third generation CoreValve Evolut PRO system and tissue & mechanical heart valves. To maintain its leading position in the market and increase its customer base, the company focuses on product launches & approvals, partnerships, and expansions. For instance, in 2016, the company partnered with the World Stroke Organization (WSO, Switzerland). Under this partnership, the two organizations will work together to educate, raise awareness, and support the effective management of patients who suffer from strokes.

Some of the other players operating in this market are CryoLife, Inc. (US), Micro Interventional Devices, Inc. (US), Braile Biomédica (Brazil), Lepu Medical Technology (Beijing) Co., Ltd. (China), and TTK Healthcare Limited (India).

Product launches & approvals; acquisitions; expansions; and partnerships & agreements were the key strategies adopted by key players between 2015 and 2018. Some of the key players that adopted these strategies are Edwards Lifesciences (US), Medtronic (Ireland), Boston Scientific (US), Abbott (US), LivaNova (UK), Micro Interventional Devices (US), Braile Biomédica (Brazil), and CryoLife (US).

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=161123753

Geographically, North America is expected to account for the largest share of the structural heart devices market in 2018, followed by Europe. The large share of North America in the global market is attributed to factors such as the rising prevalence of structural heart diseases, favourable reimbursement scenario for structural heart procedures and devices, technological advancements, and development of innovative devices.

Operating Room Integration Market Leading Players and Business Strategies

According to a new market research report Operating Room Integration Market is projected to grow at a CAGR of 12.4% during the forecast period, to reach USD 1.7 billion by 2024 from USD 1.0 billion in 2019.

The growth in this market is driven by the increasing adoption of minimally invasive surgical procedures, redevelopment projects & funding for improving OR infrastructure, and rising need to curtail healthcare costs. Also, emerging economies (such as China, India, Brazil, and Mexico) are expected to offer lucrative growth opportunities for market players during the forecast period.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=160774667

The RoW region is expected to witness the highest growth in the operating room integration market during the forecast period. The major factors driving the growth of this market include the procedural benefits of integrated ORs, growing prevalence of chronic diseases, and rising adoption of advanced surgical treatment methodologies in the region. Other factors augmenting market growth in this region are the ongoing expansion of the healthcare infrastructure as well as growing market availability of advanced surgical technologies in Brazil and other Latin American countries, ongoing initiatives of governments to enhance their respective healthcare systems and growing public-private investments for purchasing medical equipment.

Stryker Corporation (US), STERIS (US), KARL STORZ (Germany), and Olympus (Japan) are the key players operating in this market. Other prominent players in the market include Getinge (Sweden), Alvo Medical (Poland), Skytron (US), Merivaara (Finland), Brainlab (Germany), TRILUX Medical (Germany), caresyntax (US), Sony (Japan), Barco (Belgium), Arthrex (US), and Richard Wolf (Germany).

Stryker dominated the global operating room integration market in 2018. The company offers OR integration solutions through its Endoscopy division. Stryker holds a noteworthy position in the OR integration market, owing to its strong product portfolio. The company offers a full range of operating room products under the brand name—iSuite. In 2018, Stryker’s Endoscopy division recorded sales growth of 11.7%.

KARL STORZ held the second position in the operating room integration market. The company offers a wide range of endoscopic equipment for human, veterinary medicine, and industrial endoscopy. The company undertakes sales of operating room integration products through its Human Medicine business division. The company’s products are marketed through a network of 50 subsidiaries in over 40 countries across Europe, the Americas, Africa, and the Asia Pacific. With over 65 years of experience in this market, the company focuses on strengthening its sales activities and distribution network by working with an efficient network of dealers. The company also provides local-level services to its customers through its subsidiaries.

Get Report Sample @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=160774667

Olympus is a prominent and well-established player in the operating room integration market. The Medical Business of the company showed an increase in year-over-year net sales of 2.9% in 2018 over 2017. The company invests a significant amount of its revenue in research and development, which helps it launch technologically advanced products in the market. From 2017 to 2018, Olympus increased its Medical Business R&D expenditure by 10.7%.

Digital PCR Market - Growth Strategy Adopted Top Market Players | Industry Report 2024

According to research report the digital PCR market is projected to reach USD 6.3 billion by 2024 from USD 4.1 billion in 2019, at a CAGR of 8.8% from 2019 to 2024. The rising incidences of infectious diseases (such as HIV, tuberculosis, and malaria) and genetic disorders; continuous technological advancements in PCR technologies and the commercialization of lab-on-chip devices and microfluidics-based portable instruments; increasing investments, funds, and grants for genomic research; increasing use of biomarker profiling for disease diagnostics; and the successful completion of the Human Genome Project are expected to augment the growth of the global Digital PCR Market over the forecast period. On the other hand, the high instrument costs—especially that of dPCR—and the technical limitations of PCR are expected to limit market growth to a certain extent.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174151204

The major players operating in the Digital PCR Market include Thermo Fisher Scientific, Inc. (US), Takara Bio, Inc. (Japan), Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (US), Fluidigm Corporation (US), bioMérieux S.A. (France), Danaher Corporation (US), Merck KGaA (Germany), Becton Dickinson and Company (US), Eppendorf AG (Germany), Promega Corporation (US), and Analytik Jena AG (Germany).

An analysis of the market developments between 2016 and 2019 revealed that several growth strategies such as product launches; partnerships and collaborations; acquisitions; and expansions were adopted by market players to strengthen their product portfolios and maintain a competitive position in the Digital PCR Market.

Thermo Fisher Scientific (US) is one of the leading players in the field of healthcare and life science research. The company possesses a robust product portfolio in the dPCR and qPCR segment and a strong market presence globally, with sales and distribution networks in more than 50 countries. It focuses on strengthening its market position in the Digital PCR Market through product launches, acquisitions, and partnerships. The company mainly focuses on business strategies that include launching new products and gaining approvals in order to expand its product portfolio and offer customers a wide range of dPCR and qPCR products. Thermo Fisher Scientific also launched several products, including real-time PCR assay and system. It has received regulatory approvals for several other clinical assays from respective authorities. Thermo Fisher Scientific also focuses on acquisitions as a key strategy to strengthen its market position and expand its product portfolio with advanced technology products. In 2016, the company acquired Affymetrix, Inc., (US) which enabled Thermo Fisher to leverage Affymetrix’s microarray technology for novel product development.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=174151204

Bio-Rad Laboratories (US) is one of the leading players in the field of disease diagnostics & laboratory products. The company has a noteworthy presence in the dPCR and qPCR industry and a wide geographic presence in major markets such as the US, Germany, Japan, China, India, and Brazil. Bio-Rad is involved in the development, manufacturing, and marketing of more than 5,000 reagents, apparatuses, and laboratory instruments (including qPCR and dPCR products). The acquisition of RainDance Technologies in January 2017 enabled Bio-Rad to strengthen its position in the dPCR market by leveraging RainDance’s droplet microfluid technology for novel product development and product portfolio expansion. During 2015–2018, Bio-Rad Laboratories witnessed a steady rise in the profit margin & annual revenue of its Life Sciences segment through the commercialization of its dPCR and qPCR instruments, assays, and software. In the last three years, Bio-Rad has also launched several dPCR and real-time PCR (qPCR) products to meet the growing market demand for novel clinical diagnosis products by offering innovative products to its customers from the research and clinical field.

Structural Heart Devices Market - Latest Trends, Growth, Opportunities and Forecast 2027

According to research report the global structural heart devices market is expected to reach USD 19.6 billion by 2027 from USD 10.4 billion in 2019, at a CAGR of 8.2%. Growth in the structural heart devices market is mainly driven by factors such as the rising prevalence of structural heart diseases, regulatory approvals for new and advanced structural heart devices, favourable reimbursement scenario for structural heart procedures & devices, and increasing awareness about structural heart diseases.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=161123753
Objectives of the Study:
• To define, describe, and forecast the global structural heart devices market, by product, procedure, and region
• To provide detailed information regarding factors influencing market growth (drivers, restraints, opportunities, and challenges)
• To strategically analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall market
• To analyze market opportunities for stakeholders and provide details of the competitive landscape of market leaders
• To forecast the size of the structural heart devices market in North America, Europe, Asia Pacific, and the Rest of the World
• To profile the key players in the global structural heart devices market and comprehensively analyze their core competencies
• To track and analyze competitive developments, such as product launches & approvals, acquisitions, expansions, and partnerships & agreements, of the leading players in the structural heart devices market
The report describes and studies the global structural heart devices market, by product, procedure, and region.
It provides detailed information regarding the major factors influencing the growth of this market and the regulatory analysis impacting market dynamics.
On the basis of product, the global structural heart devices market is segmented into heart valve devices, occluders and delivery systems, annuloplasty rings, other devices, and accessories. The heart valve devices segment is expected to register the highest CAGR during the forecast period. The high growth of this segment can be attributed to the growing number of trans catheter aortic valve replacement procedures performed across the globe, the efficacy and durability of these products, and the growing number of regulatory approvals for heart valve devices.
Get Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=161123753
North America is expected to dominate the structural heart devices market during the forecast period
Geographically, North America is expected to account for the largest share of the structural heart devices market in 2018, followed by Europe. The large share of North America in the global market is attributed to factors such as the rising prevalence of structural heart diseases, favourable reimbursement scenario for structural heart procedures and devices, technological advancements, and development of innovative devices.
Edwards Lifesciences Corporation (US), Medtronic plc (Ireland), Abbott (US), Boston Scientific Corporation (US), and LivaNova plc (UK) are the key players in the structural heart devices market. The other players in this market are CryoLife, Inc. (US), Micro Interventional Devices, Inc. (US), Braile Biomédica (Brazil), Lepu Medical Technology (Beijing) Co., Ltd. (China), and TTK Healthcare Limited (India).

Spirometer Market – Know the Business Growth Opportunities

According to research report the global Spirometer Market is expected to reach USD 1,047 million by 2023 from USD 655 million in 2018, at a CAGR of 9.8%.

The report studies the market on the basis of product type, mechanism, application, end user, and region. Market growth is largely driven by the rising global incidence of respiratory diseases, global population, and technological advancements in spirometer devices.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=18015659

By product type, the spirometry equipment market is segmented into consumables & accessories, devices, and software. The consumables & accessories segment accounted for the largest share in 2018. The rising incidence of respiratory diseases and the growing geriatric population are the key factors driving the growth of this product segment.

Based on application, the spirometry equipment market is segmented into COPD, asthma, and other applications. Among these, the COPD segment accounted for the largest share of the spirometry equipment market in 2018. The large share of this segment is mainly due to the high and growing prevalence of COPD globally and the easy diagnosis of COPD offered by spirometry.

By end user, the spirometry equipment market is segmented into hospitals, clinical laboratories, home care settings, and industrial settings. Hospitals accounted for the largest share of the spirometry equipment market in 2018 while the home care settings segment is expected to register the highest growth during the forecast period. The growing requirement for personalized lung monitoring is a key factor driving the growth of the spirometry equipment market for home care settings.

The spirometry equipment market is geographically segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). Asia is expected to register the highest CAGR in the market during the forecast period. The high growth in this region can primarily be attributed to the rising geriatric population, high burden of respiratory diseases such as COPD and asthma, growing per capita income, increasing investments in the healthcare industry by key market players, rising demand for cutting-edge technologies, expansion of private-sector hospitals to rural areas in various APAC countries, and the presence of high-growth markets such as Japan, China, India, South Korea, Taiwan, Australia, and Singapore.

Get Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=18015659

Key players in this market can explore the possibilities of expanding to the emerging economies of India and Brazil. These countries are going through a phase of rapid industrialization, leading to increasing pollution levels. This has created a need for monitoring lung conditions regularly, which increases the demand for spirometers.